BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 10197420)

  • 1. Dose-dependent intestinal and hepatic first-pass metabolism of midazolam, a cytochrome P450 3A substrate with differently modulated enzyme activity in rats.
    Higashikawa F; Murakami T; Kaneda T; Kato A; Takano M
    J Pharm Pharmacol; 1999 Jan; 51(1):67-72. PubMed ID: 10197420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole.
    Tsunoda SM; Velez RL; von Moltke LL; Greenblatt DJ
    Clin Pharmacol Ther; 1999 Nov; 66(5):461-71. PubMed ID: 10579473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of the hepatic and intestinal first-pass metabolism of midazolam in a CYP3A drug-drug interaction model rats.
    Kanazu T; Okamura N; Yamaguchi Y; Baba T; Koike M
    Xenobiotica; 2005 Apr; 35(4):305-17. PubMed ID: 16019953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In-vivo and in-vitro metabolic clearance of midazolam, a cytochrome P450 3A substrate, by the liver under normal and increased enzyme activity in rats.
    Higashikawa F; Murakami T; Kaneda T; Takano M
    J Pharm Pharmacol; 1999 Apr; 51(4):405-10. PubMed ID: 10385212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping.
    Lee JI; Chaves-Gnecco D; Amico JA; Kroboth PD; Wilson JW; Frye RF
    Clin Pharmacol Ther; 2002 Dec; 72(6):718-28. PubMed ID: 12496753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic interaction of cytochrome P450 3A-related compounds with rhodamine 123, a P-glycoprotein substrate, in rats pretreated with dexamethasone.
    Yumoto R; Murakami T; Sanemasa M; Nasu R; Nagai J; Takano M
    Drug Metab Dispos; 2001 Feb; 29(2):145-51. PubMed ID: 11159804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of ketoconazole on the intestinal metabolism, transport and oral bioavailability of K02, a novel vinylsulfone peptidomimetic cysteine protease inhibitor and a P450 3A, P-glycoprotein dual substrate, in male Sprague-Dawley rats.
    Zhang Y; Hsieh Y; Izumi T; Lin ET; Benet LZ
    J Pharmacol Exp Ther; 1998 Oct; 287(1):246-52. PubMed ID: 9765344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of dexamethasone on the intestinal first-pass metabolism of indinavir in rats: evidence of cytochrome P-450 3A [correction of P-450 A] and p-glycoprotein induction .
    Lin JH; Chiba M; Chen IW; Nishime JA; deLuna FA; Yamazaki M; Lin YJ
    Drug Metab Dispos; 1999 Oct; 27(10):1187-93. PubMed ID: 10497146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methodologies to study the induction of rat hepatic and intestinal cytochrome P450 3A at the mRNA, protein, and catalytic activity level.
    Cotreau MM; von Moltke LL; Beinfeld MC; Greenblatt DJ
    J Pharmacol Toxicol Methods; 2000; 43(1):41-54. PubMed ID: 11091129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Model for the drug-drug interaction responsible for CYP3A enzyme inhibition. II: establishment and evaluation of dexamethasone-pretreated female rats.
    Kanazu T; Yamaguchi Y; Okamura N; Baba T; Koike M
    Xenobiotica; 2004 May; 34(5):403-13. PubMed ID: 15370957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism.
    Paine MF; Khalighi M; Fisher JM; Shen DD; Kunze KL; Marsh CL; Perkins JD; Thummel KE
    J Pharmacol Exp Ther; 1997 Dec; 283(3):1552-62. PubMed ID: 9400033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis.
    Kharasch ED; Walker A; Hoffer C; Sheffels P
    Clin Pharmacol Ther; 2004 Nov; 76(5):452-66. PubMed ID: 15536460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatic and intestinal cytochrome P450 3A activity in cirrhosis: effects of transjugular intrahepatic portosystemic shunts.
    Chalasani N; Gorski JC; Patel NH; Hall SD; Galinsky RE
    Hepatology; 2001 Dec; 34(6):1103-8. PubMed ID: 11731998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin.
    Gorski JC; Jones DR; Haehner-Daniels BD; Hamman MA; O'Mara EM; Hall SD
    Clin Pharmacol Ther; 1998 Aug; 64(2):133-43. PubMed ID: 9728893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition and kinetics of cytochrome P4503A activity in microsomes from rat, human, and cdna-expressed human cytochrome P450.
    Ghosal A; Satoh H; Thomas PE; Bush E; Moore D
    Drug Metab Dispos; 1996 Sep; 24(9):940-7. PubMed ID: 8886602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity.
    Gorski JC; Vannaprasaht S; Hamman MA; Ambrosius WT; Bruce MA; Haehner-Daniels B; Hall SD
    Clin Pharmacol Ther; 2003 Sep; 74(3):275-87. PubMed ID: 12966371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of ketoconazole on the jejunal permeability and CYP3A metabolism of (R/S)-verapamil in humans.
    Sandström R; Knutson TW; Knutson L; Jansson B; Lennernäs H
    Br J Clin Pharmacol; 1999 Aug; 48(2):180-9. PubMed ID: 10417494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between hepatic cytochrome P450 3A content and activity and the disposition of midazolam administered orally.
    Wandel C; Böcker RH; Böhrer H; deVries JX; Hofmann W; Walter K; Kleingeist B; Neff S; Ding R; Walter-Sack I; Martin E
    Drug Metab Dispos; 1998 Feb; 26(2):110-4. PubMed ID: 9456296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of human intestinal wall metabolism by macrolide antibiotics: effect of clarithromycin on cytochrome P450 3A4/5 activity and expression.
    Pinto AG; Wang YH; Chalasani N; Skaar T; Kolwankar D; Gorski JC; Liangpunsakul S; Hamman MA; Arefayene M; Hall SD
    Clin Pharmacol Ther; 2005 Mar; 77(3):178-88. PubMed ID: 15735612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of the metabolism of midazolam by rifampin in cultured porcine hepatocytes: preliminary evidence for CYP3A isoforms in pigs.
    Hosagrahara VP; Hansen LK; Remmel RP
    Drug Metab Dispos; 1999 Dec; 27(12):1512-8. PubMed ID: 10570035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.